CER is a “historical market opportunity”; Quintiles VP

By Nick Taylor

- Last updated on GMT

Related tags Clinical trial Contract research organization

Comparative effectiveness research (CER) represents a “historical market opportunity”, according to a VP at Quintiles who explained that pharmas that do the work will be “properly rewarded for their innovations”.

The US economic stimulus bill allocated $1.1bn (€734m) to CER, pushing the topic into the limelight, and John Doyle, vice president (VP), practice leader at Quintiles Consulting, believes pharma needs to capitalise on this opportunity.

In a white paper Doyle states that if pharma takes the lead on this issue it can put itself in a position where it “can drive the establishment of a product valuation system that compensates innovation fairly​”.

To achieve this pharma will need to embrace CER, which evaluates the real world performance of a new product against the current standard of care, and this could create opportunities for contract research organisations (CRO).

Doyle envisages a new product being compared to the existing treatment in a variety of patient populations across multiple benefit and risk metrics. The clinical trial expertise at CROs, and pharma’s desire to outsource, could see them benefit if CER becomes commonplace.

Pharma perspective

Doyle believes that pharma “can simply not afford to wait passively for policy-makers to dictate comparative effectiveness requirements​”. By a proactive approach Doyle believes that pharma can play a role in discussions regarding the proper design and use of CER.

This could lead to the development of a widely accepted, standardised format for CER that companies can use alongside a product’s traditional data demonstrations.

Doyle added that products supported by CER will be better equipped to demonstrate value to multiple stakeholders, ensuring that companies with truly innovative therapeutics that have real benefit to patients will be paid accordingly.

Furthermore, Doyle believes that CER can complement randomised clinical trials to help companies refine development and product positioning before a drug’s launch.

The complete white paper is available here​.

Related news

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Related suppliers

Follow us


View more